Semisynthesis of Glycosmis pentaphylla Alkaloid Derivatives: Pyranoacridone-Hydroxamic Acid Cytotoxic Conjugates with HDAC and Topoisomerase II α Dual Inhibitory Activity
- PMID: 39772592
- DOI: 10.1021/acs.jnatprod.4c00843
Semisynthesis of Glycosmis pentaphylla Alkaloid Derivatives: Pyranoacridone-Hydroxamic Acid Cytotoxic Conjugates with HDAC and Topoisomerase II α Dual Inhibitory Activity
Abstract
Inspired by our previous efforts in the semisynthetic modification of naturally occurring pyranoacridones, we report the targeted design and semisynthesis of dual inhibitors of HDAC and topoisomerase II α (Topo II α) derived from Glycosmis pentaphylla des-N-methylacronycine (1) and noracronycine (8) pyranoacridone alkaloids. Designed from the clinically approved SAHA, the cytotoxic pyranoacridone nuclei from the alkaloids served as the capping group, while a hydroxamic acid moiety functioned as the zinc-binding group. Out of 16 compounds evaluated in an in vitro cytotoxicity assay, KT32 (10c) with noracronycine (8) as the capping group and five-carbon linker hydroxamic acid side chains showed good cytotoxic activity with IC50 values of 1.0, 1.5, and 0.3 μM on MCF-7, CALU-3, and SCC-25 cell lines, respectively. KT32 (10c) showed potent HDAC inhibitory activity and partial Topo II α inhibitory activity in both enzyme assays. The SAR results strongly aligned with the predicted binding affinities from the molecular docking study. KT32 (10c) was further explored for a preliminary mechanistic understanding of SCC-25 cell lines. Flow cytometry analysis suggests that KT32 (10c) induces cell death through apoptosis, as evidenced by the substantial increase in the population of late apoptotic cells.
Similar articles
-
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.Bioorg Med Chem. 2018 Aug 7;26(14):3958-3966. doi: 10.1016/j.bmc.2018.06.016. Epub 2018 Jun 20. Bioorg Med Chem. 2018. PMID: 29954683
-
The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.Bioorg Med Chem. 2013 Nov 15;21(22):6981-95. doi: 10.1016/j.bmc.2013.09.023. Epub 2013 Sep 18. Bioorg Med Chem. 2013. PMID: 24095018
-
Isolation, Characterization of Undescribed Alkaloids, and Semisynthetic Modifications of Cytotoxic Pyranoacridone Alkaloids from Glycosmis pentaphylla.ACS Omega. 2023 Mar 13;8(12):11201-11212. doi: 10.1021/acsomega.2c08100. eCollection 2023 Mar 28. ACS Omega. 2023. PMID: 37008118 Free PMC article.
-
In vivo Anticancer Potential of Hydroxamic Acid Derivatives.Curr Top Med Chem. 2021;21(19):1737-1755. doi: 10.2174/1568026621666210813105240. Curr Top Med Chem. 2021. PMID: 34392823 Review.
-
A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors.Bioorg Chem. 2025 Mar;156:108169. doi: 10.1016/j.bioorg.2025.108169. Epub 2025 Jan 20. Bioorg Chem. 2025. PMID: 39862739 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous